* NeoRx Corp., of Seattle, said a single dose of Avicidin cancertherapy product cured nude mice bearing human lung, colon andbreast cancers at doses causing no normal tissue toxicity. Data werepresented last Friday at the Fifth Conference onRadioimmunodetection and Radioimmunotherapy of Cancer inPrinceton, N.J. The company's stock, which closed at $3.88 pershare Friday, has surged since then. It gained $1.94 Tuesday andanother 88 cents Wednesday, in trading of nearly 2 million shares,to close at $7.75.* Alteon Inc., of Ramsey, N.J., said a study presented at The 80thClinical Congress of the American College of Surgeons in Chicagodemonstrated that pimagedine mitigates the severity of stroke inexperimental rats.* Target Therapeutics Inc., of Fremont, Calif., formed a newGerman subsidiary, Target Therapeutics International DeutschlandGmbH, by purchasing certain assets from Rehaforum MedicalGmbH.* Cambridge NeuroScience Inc., of Cambridge, Mass., reported thatprogressive improvements were seen in cerebral perfusion pressureand intracranial pressure in patients treated with Cerestat, giving thecompany additional encouraging results from a safety study.* GeneMedicine Inc., of Houston, received its third Phase I SmallBusiness Innovation Research grant. The $81,000 grant will aid indevelopment of synthetic muscle-specific gene expression systemsto provide high levels of cell-specific gene expression.* ImmunoTherapeutics Inc., of Fargo, N.D., said it repurchased629,624 shares of its common stock and 412,953 1997 warrants for$300,000.
(c) 1997 American Health Consultants. All rights reserved.